高级检索
当前位置: 首页 > 详情页

Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [2]Department of Cardiothoracic Surgery, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
出处:
ISSN:

关键词: DNA damage repair (DDR) esophageal squamous cell carcinoma (ESCC) immunotherapy response prognosis single-cell analysis

摘要:
The relationship between DNA damage repair (DDR) and cancer is intricately intertwined; however, its specific role in esophageal squamous cell carcinoma (ESCC) remains enigmatic.Employing single-cell analysis, we delineated the functionality of DDR-related genes within the tumor microenvironment (TME). A diverse array of scoring mechanisms, including AUCell, UCell, singscore, ssgsea, and AddModuleScore, were harnessed to scrutinize the activity of DDR-related genes across different cell types. Differential pathway alterations between high-and low-DDR activity cell clusters were compared. Furthermore, leveraging multiple RNA-seq datasets, we constructed a robust DDR-associated signature (DAS), and through integrative multiomics analysis, we explored differences in prognosis, pathways, mutational landscapes, and immunotherapy predictions among distinct DAS groups.Notably, high-DDR activity cell subpopulations exhibited markedly enhanced cellular communication. The DAS demonstrated uniformity across multiple datasets. The low-DAS group exhibited improved prognoses, accompanied by heightened immune infiltration and elevated immune checkpoint expression. SubMap analysis of multiple immunotherapy datasets suggested that low-DAS group may experience enhanced immunotherapy responses. The "oncopredict" R package analyzed and screened sensitive drugs for different DAS groups.Through the integration of single-cell and bulk RNA-seq data, we have developed a DAS associated with prognosis and immunotherapy response. This signature holds promise for the future stratification and personalized treatment of ESCC patients in clinical settings.© 2024 Wiley Periodicals LLC.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 2 区 环境科学 2 区 毒理学 2 区 水资源
最新[2023]版:
大类 | 3 区 医学
小类 | 2 区 环境科学 2 区 毒理学 2 区 水资源
第一作者:
第一作者机构: [1]Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [*1]Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43370 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号